2024
Food Insecurity and Hypoglycemia among Older Patients with Type 2 Diabetes Treated with Insulin or Sulfonylureas: The Diabetes & Aging Study
Karter A, Parker M, Huang E, Seligman H, Moffet H, Ralston J, Liu J, Gilliam L, Laiteerapong N, Grant R, Lipska K. Food Insecurity and Hypoglycemia among Older Patients with Type 2 Diabetes Treated with Insulin or Sulfonylureas: The Diabetes & Aging Study. Journal Of General Internal Medicine 2024, 39: 2400-2406. PMID: 38767746, PMCID: PMC11436613, DOI: 10.1007/s11606-024-08801-y.Peer-Reviewed Original ResearchType 2 diabetes treated with insulinOlder patientsSevere hypoglycemiaFood insecurityAssociated with severe hypoglycemiaCharlson comorbidity scoreFood insecurity questionsCross-sectional studyComorbidity scoreSelf-reported reasonsMissed mealsHigh riskRisk factorsPatientsHypoglycemiaResultsFood insecurityFinancial strainDiabetesPrevention effortsAging StudySulfonylureaMedicationInsulinAgeRiskFeasibility and Acceptability of an Agenda-Setting Kit in the Care of People With Type 2 Diabetes: The QBSAFE ASK Feasibility Study
Haider S, Gonzalez-Lopez C, Clark J, Gravholt D, Breslin M, Boehmer K, Hartasanchez S, Sanchez B, Montori V, Lipska K. Feasibility and Acceptability of an Agenda-Setting Kit in the Care of People With Type 2 Diabetes: The QBSAFE ASK Feasibility Study. Clinical Diabetes 2024, 42: 358-363. PMID: 39015172, PMCID: PMC11247036, DOI: 10.2337/cd23-0062.Peer-Reviewed Original Research
2023
1217-P: Willingness to Deintensify in Patients with Type 2 Diabetes—The Diabetes and Aging Study
HAIDER S, PARKER M, HUANG E, GRANT R, MOFFET H, LAITEERAPONG N, LIU J, LIPSKA K, KARTER A. 1217-P: Willingness to Deintensify in Patients with Type 2 Diabetes—The Diabetes and Aging Study. Diabetes 2023, 72 DOI: 10.2337/db23-1217-p.Peer-Reviewed Original ResearchType 2 diabetesOlder patientsKaiser Permanente Northern CaliforniaDe-intensify treatmentDuration of diabetesGlucose-lowering medicationsNumber of medicationsProportion of patientsClinical guideline recommendationsHealth status factorsPoor health statusCross-sectional analysisInsulin useComplex regimensLess medicationGuideline recommendationsPatients' willingnessAbbVie Inc.Side effectsDiabetesPatient experiencePatientsHealth statusHypoglycemia historyMedications1356-P: Association of HbA1c with Diabetes Outcomes across Health Status Categories in Older Adults
LIPSKA K, HUANG E, LIU J, PARKER M, MOFFET H, GRANT R, LAITEERAPONG N, KARTER A. 1356-P: Association of HbA1c with Diabetes Outcomes across Health Status Categories in Older Adults. Diabetes 2023, 72 DOI: 10.2337/db23-1356-p.Peer-Reviewed Original ResearchComplication riskPoor healthIntermediate healthOlder adultsGood healthIntegrated healthcare delivery systemAssociation of HbA1cType 2 diabetesProportional hazards modelNational InstituteHealth status categoriesHealthcare delivery systemEligible patientsMacrovascular eventsSevere hypoglycemiaKidney diseaseClinical variablesDiabetes outcomesEndocrine SocietyAbbVie Inc.Hazards modelComplicationsHealth statusTwin healthPatients719-P: Feasibility and Acceptability of the Quality of Life, Burden of Treatment, Safety, and Avoidance of Future Events Agenda Setting Kit (QBSAFE ASK)
HAIDER S, GONZALEZ LOPEZ C, CLARK J, GRAVHOLT D, BRESLIN M, BOEHMER K, HARTASANCHEZ S, SANCHEZ B, MONTORI V, LIPSKA K. 719-P: Feasibility and Acceptability of the Quality of Life, Burden of Treatment, Safety, and Avoidance of Future Events Agenda Setting Kit (QBSAFE ASK). Diabetes 2023, 72 DOI: 10.2337/db23-719-p.Peer-Reviewed Original ResearchSingle-arm intervention studyStudy proceduresRoutine clinic visitsBurden of treatmentDiabetes-related topicsQuality of lifeClinic visitsMost patientsDiabetes carePatient goalsClinical careClinician responsesPatientsParticipant enrollmentIntervention studiesCliniciansAcceptability surveyCommon beingNational InstituteConversation CardsCareTreatmentEnrollmentAcceptabilityDiabetes
2021
864-P: Treatment Burden and Quality of Life Conversations during Clinical Encounters: A Videographic Analysis
HAIDER S, EL KAWKGI O, CLARK J, BRESLIN M, BOEHMER K, MONTORI V, LIPSKA K. 864-P: Treatment Burden and Quality of Life Conversations during Clinical Encounters: A Videographic Analysis. Diabetes 2021, 70 DOI: 10.2337/db21-864-p.Peer-Reviewed Original ResearchTreatment burdenDiabetes mellitusSexual functionDiagnosis of DMClinical encountersSocial supportInternal medicine clinicPatient-clinician encountersClinician-patient encountersQuality of lifeCommon complicationDiabetes careMedicine clinicSexual dysfunctionPatient concernsPatient experienceSignificant burdenHypoglycemiaQoLProvider responsesPatientsVideographic analysisLife conversationsFamily medicineClinicians882-P: QBSAFE: Pilot Study of an Intervention to Shift the Paradigm of Diabetes Care
CLARK J, BOEHMER K, BRESLIN M, HAIDER S, PASCIAK W, GRAVHOLT D, SANCHEZ B, HARTASANCHEZ S, EL KAWKGI O, MONTORI V, LIPSKA K. 882-P: QBSAFE: Pilot Study of an Intervention to Shift the Paradigm of Diabetes Care. Diabetes 2021, 70 DOI: 10.2337/db21-882-p.Peer-Reviewed Original ResearchDiabetes careSingle-arm pilot studyClinical encountersPilot studyMedication side effectsSubgroup of patientsBurden of treatmentFocus of careAddress patients' needsClinician-patient conversationsPost-visit surveysQuality of lifeRoutine clinical encountersHigh treatment costsUsual careGlycemic controlClinical visitsPatient participantsClinician participantsSide effectsPatientsPatient needsCliniciansTreatment costsQualitative semi-structured interviews
2020
379-P: Glucagon Use by U.S. Adults with Type 1 and Type 2 Diabetes
KAHN P, LIU S, MCCOY R, GABBAY R, LIPSKA K. 379-P: Glucagon Use by U.S. Adults with Type 1 and Type 2 Diabetes. Diabetes 2020, 69 DOI: 10.2337/db20-379-p.Peer-Reviewed Original ResearchType 2 diabetesHigh-risk patientsType 1Diabetes patientsGlucagon useType 1 diabetes patientsAmerican Diabetes AssociationType 1 diabetesMedicare Advantage enrolleesPoor discriminative performanceGlucagon prescriptionsPrior hypoglycemiaRisk patientsDiabetes AssociationPrescribing practicesEndocrinology careMultivariable modelAdministrative claimsHigh riskPatientsType 2DiabetesModel AUCU.S. adultsGlucagon
2019
1249-P: Development and Validation of a Measure for Appropriateness of Glucose-Lowering Therapy
MCCOY R, LIPSKA K, HOUTEN H, SHAH N. 1249-P: Development and Validation of a Measure for Appropriateness of Glucose-Lowering Therapy. Diabetes 2019, 68 DOI: 10.2337/db19-1249-p.Peer-Reviewed Original ResearchGlucose lowering therapiesOptimal therapeutic regimensGlucose lowering medicationsDiabetes quality indicatorsNational InstituteMedicare Advantage enrolleesPatient-centered approachHigh-complexity patientsPerson/yearComorbidity burdenHospitalization visitsTreatment burdenHypoglycemia riskKidney diseaseTherapeutic regimensNational cohortNumber/typeClinical complexityPatientsMedicaid ServicesOptumLabsDiabetesTherapyVisitsAmerican Association
2018
Cost-Related Insulin Underuse Is Common and Associated with Poor Glycemic Control
HERKERT D, VIJAYAKUMAR P, LUO J, SCHWARTZ J, RABIN T, DEFILIPPO E, LIPSKA K. Cost-Related Insulin Underuse Is Common and Associated with Poor Glycemic Control. Diabetes 2018, 67 DOI: 10.2337/db18-2-or.Peer-Reviewed Original ResearchCost-related underusePoor glycemic controlGlycemic controlDiabetes CenterCross-sectional surveyDM durationPrimary outcomeLess insulinHigher oddsPatientsSmall dosesDrug coverageLogistic regressionInsulinUnderuseMedicaid ServicesEssential medicinesNational InstituteInsulin 3Lower income levelsInsulin 5AgePositive responseHealthUrgent need
2017
ADMISSION TYPES AMONG PATIENTS WITH HEART FAILURE CARED FOR BY ACCOUNTABLE CARE ORGANIZATIONS: VARIATION BY PERFORMANCE ON A MEASURE OF RISK STANDARDIZED ACUTE ADMISSION RATES
Benchetrit L, Zimmerman C, Bao H, Dharmarajan K, Atlaf F, Herrin J, Lin Z, Krumholz H, Drye E, Lipska K, Spatz E. ADMISSION TYPES AMONG PATIENTS WITH HEART FAILURE CARED FOR BY ACCOUNTABLE CARE ORGANIZATIONS: VARIATION BY PERFORMANCE ON A MEASURE OF RISK STANDARDIZED ACUTE ADMISSION RATES. Journal Of The American College Of Cardiology 2017, 69: 762. DOI: 10.1016/s0735-1097(17)34151-7.Peer-Reviewed Original Research
2008
Cardiovascular risk-benefit ratio of thiazolidinediones
Lipska K, Inzucchi S. Cardiovascular risk-benefit ratio of thiazolidinediones. Current Cardiovascular Risk Reports 2008, 3: 42-50. DOI: 10.1007/s12170-009-0008-9.Peer-Reviewed Original ResearchRisk-benefit ratioType 2 diabetes mellitusActual cardiovascular outcomesSurrogates of atherosclerosisDifferential clinical effectsInsulin-sensitizing thiazolidinedionesEffective antihyperglycemic agentCardiovascular eventsCardiovascular outcomesCardiovascular implicationsBlood pressureDiabetes mellitusEndothelial functionHeart failureClinical effectsInsulin resistanceAntihyperglycemic agentsFluid retentionLipid profileThiazolidinedionesPatientsAvailable membersBeneficial impactMellitusT2DM